Supreme Court Extends Telemedicine Access to Abortion Pill Mifepristone

The U.S. Supreme Court has extended the temporary allowance for telemedicine prescriptions and mail delivery of the abortion pill mifepristone until at least May 14, 2026, as it reviews ongoing legal challenges.

Justice Samuel Alito issued the extension on May 11, 2026, maintaining the current prescribing rules that permit patients to obtain mifepristone via telehealth consultations and mail delivery. This decision follows a previous stay granted by Alito, which was set to expire on May 11. The extension provides the Court additional time to consider the case brought by Louisiana challenging the Food and Drug Administration's (FDA) regulations on mifepristone distribution.

The legal dispute began when Louisiana filed a lawsuit against the FDA, arguing that the agency's rules allowing telemedicine prescriptions and mail delivery of mifepristone undermined the state's abortion ban. In 2023, the FDA had lifted the requirement for in-person dispensing of the drug, enabling remote access through telehealth services. Louisiana contends that this change circumvents its state laws restricting abortion access.

Mifepristone, approved by the FDA in 2000, is commonly used in combination with misoprostol for medication abortions. The availability of these medications through telehealth has become a significant aspect of abortion access, particularly following the Supreme Court's 2022 decision to overturn Roe v. Wade. The current legal proceedings have implications for the FDA's authority to regulate drug distribution and for the broader landscape of abortion access in the United States.

As the Supreme Court deliberates, healthcare providers and patients await further guidance on the future availability of mifepristone through telemedicine and mail delivery services.